(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.
Interim analysis of the ECHO Phase III trial shows that Calquence, otherwise known as acalabrutinib - when used with a combination of standard-of-care chemoimmunotherapy,...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE